SILO - Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA | Benzinga
Pre-IND submission to FDA targeted for first quarter 2024
Silo partners with Kymanox for SPC-15
ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA). SPC-15 is a targeted intranasal prophylactic intended for the treatment and prevention of anxiety, PTSD, and other stress-related disorders.
"Our pre-clinical data indicate that SPC-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels. In conjunction with Columbia University, we are pleased to announce this milestone in advancing our potential therapeutic development for those suffering from stress-induced anxiety and PTSD. We are confident that our own pre-clinical work coupled with published preclinical data provides a strong foundation for our pre-IND application, which we plan to submit during the first quarter ...